Investors Buy Shares of Pfizer (PFE) on Weakness

Traders bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Tuesday. $295.88 million flowed into the stock on the tick-up and $257.36 million flowed out of the stock on the tick-down, for a money net flow of $38.52 million into the stock. Of all companies tracked, Pfizer had the 23rd highest net in-flow for the day. Pfizer traded down ($1.22) for the day and closed at $37.80

A number of equities analysts have weighed in on PFE shares. Morningstar set a $38.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research report on Wednesday, December 27th. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a research report on Wednesday, January 24th. Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Finally, Sanford C. Bernstein set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $38.50.

The firm has a market capitalization of $225,310.00, a P/E ratio of 23.19, a PEG ratio of 2.41 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter in the prior year, the business posted $0.47 EPS. The business’s revenue was up .6% compared to the same quarter last year. equities research analysts expect that Pfizer Inc. will post 2.6 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date of this dividend is Thursday, February 1st. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is 78.53%.

Pfizer announced that its board has authorized a share repurchase plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,450 shares of company stock worth $1,065,220. 0.06% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC increased its position in Pfizer by 243.5% during the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after buying an additional 9,339,749 shares during the period. Vanguard Group Inc. increased its position in Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after buying an additional 9,239,499 shares during the period. Renaissance Technologies LLC bought a new position in Pfizer during the 2nd quarter worth $268,389,000. Canada Pension Plan Investment Board increased its position in Pfizer by 249.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after buying an additional 7,649,416 shares during the period. Finally, Stifel Financial Corp increased its position in Pfizer by 5,413.5% during the 3rd quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock worth $262,515,000 after buying an additional 7,226,697 shares during the period. Institutional investors and hedge funds own 69.87% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/30/investors-buy-shares-of-pfizer-pfe-on-weakness.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply